
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.






